Advertisement

Journal of Nephrology

, Volume 32, Issue 5, pp 843–846 | Cite as

Correction to: Role of anemia and proteinuria in the development of subsequent renal function deterioration in a general population with preserved glomerular filtration rate: a community-based cohort study

  • Hiroyuki Kiriyama
  • Hidehiro KanekoEmail author
  • Hidetaka Itoh
  • Yuriko Yoshida
  • Koki Nakanishi
  • Yoshiko Mizuno
  • Masao Daimon
  • Hiroyuki Morita
  • Yutaka Yatomi
  • Issei Komuro
Correction
  • 291 Downloads

Correction to: Journal of Nephrology  https://doi.org/10.1007/s40620-019-00605-2

After the online first publication of their research, the authors realized they made several mistakes in the data conversion process from the original data of health check-up at the Center for Preventive Medicine at The University of Tokyo Hospital to the datasheet which was used for the statistical analysis by SPSS. Particularly, the prevalence of hypertension, diabetes mellitus, and hypercholesterolemia was not appropriately analyzed. Therefore, the authors re-analyzed the data according to the corrected database.

Methods and results in the Abstract should read as it follows:

Among 3217 subjects who underwent repeated health check-ups, we excluded 478 subjects with eGFR < 60 mL/min/1.73 m2 and examined 2739 subjects. EGFR decline rate was calculated from the difference in eGFR between the first and last visits. EGFR decline, which was defined as a drop in GFR accompanied by a 25% or greater drop in eGFR from baseline and/or a sustained decline of more than 5 mL/min/1.73 m2/year, was observed in 209 subjects (7.6%).

Anemia according to the WHO definition (16.7% vs. 11.7%, p = 0.03), and proteinuria (3.3% vs. 0.8%, p = 0.001) at baseline were more commonly observed in subjects with eGFR decline. Multivariable logistic regression analysis showed that anemia and proteinuria were independently associated with eGFR decline.

In the “Methods” section the sub-heading “Measurement of covariates” should begin with

At baseline, general information and prior medical history were recorded by a standard interview. Body mass index was calculated in kg/m2. Hypertension was defined as a blood pressure ≥ 140/90 mmHg or use of antihypertensive medications. Diabetes mellitus (DM) was defined by fasting glucose ≥ 126 mg/dL or use of insulin or oral antidiabetic medications. Hypercholesterolemia was defined by total cholesterol > 240 mg/dL or use of antihypercholesterolemic medications.

In the “Results” section under the sub-heading “Baseline characteristics”

Anemia was more common in the eGFR decline group than in the eGFR non-decline group (11.7% vs. 16.7%; p = 0.03). EGFR at baseline was significantly higher in the eGFR decline group (76.9 ± 11.7 mL/min/1.73 m2 vs. 85.4 ± 21.4 mL/min/1.73 m2; p < 0.001), eGFR at the last visit was significantly higher in the eGFR non-decline group (75.2 ± 12.6 mL/min/1.73 m2 vs. 71.5 ± 20.4 mL/min/1.73 m2; p = 0.011)

the last sentence should read as it follows:

Proteinuria was more commonly observed in the eGFR decline group (3.3% vs. 0.8%, p = 0.001).

In the “Results” section under the sub-heading “Determinants of eGFR decline”

Multivariable logistic regression analysis including gender, age (≥ 60 years old), body mass index (> 25 kg/m2), hypertension, DM, hypercholesterolemia, hyperuricemia, history of smoking, eGFR at baseline (> 75 mL/min/1.73 m2), CRP (> 0.3 mg/dL), anemia, and proteinuria showed that higher eGFR [odds ratio (OR), 1.86; p < 0.001], anemia (OR 1.56; p = 0.03) and proteinuria (OR 5.22; p = 0.001) were independent predictors of eGFR decline

In the “Results” section under the sub-heading “Subgroup analysis”

Study subjects were divided into two groups based on the presence of DM. The baseline characteristics in each group are shown in Appendix tables A/B. eGFR decline was seen in 16 of 190 subjects with DM (8.4%) and in 193 of 2549 subjects without DM (7.6%). In subjects with DM, anemia was not observed in subjects with eGFR decline, and therefore, OR of anemia for eGFR decline could not be calculated. Proteinuria tended to be associated with eGFR decline (OR 7.18; p = 0.09). In subjects without DM, anemia (OR 1.63; p = 0.02) and proteinuria (OR 4.44; p = 0.007) were associated with eGFR decline.

The corrected tables are given below. The conclusions of the published article are not affected.
Table 1

Baseline clinical characteristics

Variable

Overall (n = 2739)

eGFR non-decline group (n = 2530)

eGFR decline group (n = 209)

p value

Gender (male)

1519 (55.5)

1410 (55.7)

109 (52.2)

0.32

Age (year)

58.9 ± 11.8

58.9 ± 11.8

58.5 ± 11.5

0.67

Follow-up period (day)

1233 ± 494

1278 ± 472

686 ± 414

< 0.001

BMI

22.9 ± 3.4

22.9 ± 3.4

22.6 ± 3.2

0.16

Systolic blood pressure (mmHg)

118.6 ± 15.4

118.8 ± 15.5

116.7 ± 14.4

0.06

Diastolic blood pressure (mmHg)

74.9 ± 10.0

75.0 ± 9.9

73.6 ± 11.2

0.06

Pulse rate (bpm)

72.7 ± 10.7

72.7 ± 10.8

72.7 ± 10.5

0.99

Lifestyle

 History of smoking

  Current

323/2727 (11.8)

293/2518 (11.6)

30 (14.4)

0.24

  Former

726/2727 (26.6)

674/2518 (26.8)

52 (24.9)

0.55

  Never

1678/2727 (61.5)

1551/2518 (61.6)

127 (60.8)

0.81

 Comorbidities

  Hypertension

769 (28.1)

721 (28.5)

48 (23.0)

0.09

  Diabetes mellitus

190 (6.9)

174 (6.9)

16 (7.7)

0.67

  Hypercholesterolemia

834 (30.4)

782 (30.9)

52 (24.9)

0.07

  Fatty liver

338 (12.3)

320 (12.6)

18 (8.6)

0.09

  Gout

145 (5.3)

137 (5.4)

8 (3.8)

0.33

  Metabolic syndrome

336 (12.3)

315 (12.5)

21 (10.0)

0.31

  Atrial fibrillation

19 (0.7)

19 (0.8)

0 (0)

0.21

  Anemia

330 (12.0)

295 (11.7)

35 (16.7)

0.03

  Previous CVD

102 (3.7)

93 (3.7)

9 (4.3)

0.64

 Laboratory data

  Hemoglobin (g/dL)

14.1 ± 1.4

14.2 ± 1.3

13.8 ± 1.5

< 0.001

  BUN (mg/dL)

14.1 ± 3.4

14.2 ± 3.4

13.6 ± 3.8

0.02

  Creatinine (mg/dL)

0.73 ± 0.14

0.74 ± 0.14

0.67 ± 0.14

< 0.001

  eGFR (mL/min/1.73 m2)

77.5 ± 12.9

76.9 ± 11.7

85.4 ± 21.4

< 0.001

  eGFR (last visit), (mL/min/1.73 m2)

74.9 ± 13.4

75.2 ± 12.6

71.5 ± 20.4

0.011

  ∆eGFR change (mL/min/1.73 m2 year)

− 0.83 ± 3.63

− 0.21 ± 2.79

− 8.41 ± 4.0

< 0.001

  HbA1c (%)

5.7 ± 0.5

5.7 ± 0.5

5.7 ± 0.7

0.07

  Total cholesterol (mg/dL)

206.0 ± 34.0

206.5 ± 33.9

199.6 ± 35.2

0.005

  LDL-C (mg/dL)

125.5 ± 30.5

126.0 ± 30.4

120.2 ± 32.2

0.01

  HDL-C (mg/dL)

67.6 ± 18.4

67.8 ± 18.4

66.0 ± 18.5

0.18

  Uric acid (mg/dL)

5.5 ± 1.3

5.5 ± 1.3

5.4 ± 1.4

0.78

  CRP (mg/dL)

0.11 ± 0.45

0.10 ± 0.34

0.21 ± 1.10

0.155

 Urine test

  Proteinuria

28/2727 (1.0)

21/2518 (0.8)

7 (3.3)

0.001

Data are expressed as mean ± standard deviation or number (%)

eGFR estimated glomerular filtration rate, BMI body mass index, CVD cardiovascular disease, BUN blood urea nitrogen, LDL-C low density lipoprotein cholesterol, HDL-C high density lipoprotein cholesterol, CRP C-reactive protein

Table 2

Determinants of eGFR decline

Variable

p value

Odds ratio

95% CI

Male gender

0.26

0.84

0.62–1.14

Age ≥ 60 years old

0.55

0.92

0.69–1.22

Body mass index > 25 kg/m2

0.96

0.99

0.70–1.42

Hypertension

0.09

0.73

0.51–1.05

Diabetes mellitus

0.45

1.24

0.71–2.16

Hypercholesterolemia

0.17

0.79

0.56–1.11

Gout

0.62

0.83

0.39–1.75

History of smoking

0.51

1.11

0.82–1.50

eGFR at baseline > 75 mL/min/1.73 m2

< 0.001

1.86

1.38–2.52

CRP > 0.3 mg/dL

0.17

1.48

0.85–2.59

Anemia

0.03

1.56

1.04–2.35

Proteinuria

0.001

5.22

2.04–13.34

CI confidence interval, eGFR estimated glomerular filtration rate, CRP C-reactive protein

Table 3

Multivariable analysis (subgroup analysis)

Variable

Diabetes mellitus absent

Diabetes mellitus present

Adjusted OR (95% CI)

p value

Adjusted OR (95% CI)

p value

Anemia

1.63 (1.08–2.46)

0.02

– (–)

Proteinuria

4.44 (1.51–13.1)

0.007

7.18 (0.76–68.2)

0.09

Adjusted for male, age ≥ 60 years, BMI > 25 kg/m2, hypertension, hypercholesterolemia, gout, history of smoking, eGFR at baseline > 75 mL/min/1.73 m2, CRP > 0.3 mg/dL

CI confidence interval, OR odds ratio

Appendix Table A: Subgroup analysis (DM present)

Variable

Overall (n = 190)

eGFR non-decline group (n = 174)

eGFR decline group (n = 16)

p value

Gender (male)

107 (56.3)

99 (56.9)

8 (50.0)

0.60

Age (year)

59.1 ± 12.2

59.4 ± 12.5

56.1 ± 8.2

0.29

eGFR (mL/min/1.73 m2)

78.5 ± 15.2

78.5 ± 15.2

79.0 ± 15.2

0.89

eGFR (last visit), (mL/min/1.73 m2)

77.0 ± 17.3

78.2 ± 17.1

64.3 ± 13.7

0.001

∆eGFR change (mL/min/1.73 m2 year)

− 0.05 ± 4.20

0.60 ± 3.68

− 7.15 ± 2.73

< 0.001

Hemoglobin (g/dL)

14.5 ± 1.2

14.6 ± 1.3

14.3 ± 1.2

0.47

Anemia

9 (4.7)

9 (5.2)

0 (0.0)

0.35

Proteinuria

6/188 (3.2)

4/172 (2.3)

2 (12.5)

0.03

Data are expressed as mean ± standard deviation or number (%)

DM diabetes mellitus, eGFR estimated glomerular filtration rate

Appendix Table B: Subgroup analysis (DM Absent)

Variable

Overall (n = 2549)

eGFR non-decline group (n = 2356)

eGFR decline group (n = 193)

p value

Gender (male)

1412 (55.4)

1311 (55.6)

101 (52.3)

0.37

Age (year)

58.8 ± 11.7

58.9 ± 11.7

58.7 ± 11.7

0.89

eGFR (mL/min/1.73 m2)

77.4 ± 12.8

76.7 ± 11.4

86.0 ± 21.7

< 0.001

eGFR (last visit), (mL/min/1.73 m2)

74.7 ± 13.1

74.9 ± 12.2

72.1 ± 20.8

0.003

∆eGFR change (mL/min/1.73 m2 year)

− 0.89 ± 3.58

− 0.27 ± 2.71

− 8.51 ± 4.09

< 0.001

Hemoglobin (g/dL)

14.1 ± 1.4

14.1 ± 1.3

13.7 ± 1.5

< 0.001

Anemia

321 (12.6)

286 (12.1)

35 (18.1)

0.02

Proteinuria

22/2539 (0.9)

17/2346 (0.7)

5 (2.6)

0.007

Data are expressed as mean ± standard deviation or number (%)

DM diabetes mellitus, eGFR estimated glomerular filtration rate

Notes

Copyright information

© Italian Society of Nephrology 2019

Authors and Affiliations

  • Hiroyuki Kiriyama
    • 1
  • Hidehiro Kaneko
    • 1
    • 2
    Email author
  • Hidetaka Itoh
    • 1
  • Yuriko Yoshida
    • 1
  • Koki Nakanishi
    • 1
  • Yoshiko Mizuno
    • 1
  • Masao Daimon
    • 1
    • 3
  • Hiroyuki Morita
    • 1
  • Yutaka Yatomi
    • 3
  • Issei Komuro
    • 1
  1. 1.The Department of Cardiovascular MedicineThe University of TokyoTokyoJapan
  2. 2.The Department of Advanced CardiologyThe University of TokyoTokyoJapan
  3. 3.The Department of Clinical LaboratoryThe University of Tokyo HospitalTokyoJapan

Personalised recommendations